QUANTUM GENOMICS: Quantum Genomics announced that it will present results from its Phase 3 FRESH study in refractory/refractory hypertension at the American Heart Association (AHA) Annual Meeting on November 4, 2022. 07:30

Quantum Genomics Announces Results Announcement

Phase 3 FRESH trial results in refractory/refractory hypertension,

November 4, 2022 at the American Heart Association (AHA) Annual Meeting

Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC)

is a biopharmaceutical company specializing in the development of a new class of drugs that act directly on the brain to treat difficult/refractory hypertension and heart failure and is conducting the Phase 3 FRESH trial in difficult/refractory hypertension. announced the results. Tolerant Hypertension in the “Late Exam” Session at the Annual Meeting of the American Heart Association (AHA) in Chicago (USA).

Results from the Phase 3 FRESH trial will be presented in the “Recent Studies” session on November 4, 2022 by Pr BAKRIS, the study’s principal investigator, professor of medicine, and director of the AHA2 Comprehensive Hypertension Center. will be announced. University of Chicago (USA).

Quantum Genomics Medical Director Bruno Besse said:

“Presentation of the results of the FRESH study at a conference as prestigious as the American Heart Association conference will stimulate the scientific community’s interest in new therapeutic classes, such as those represented by filibastat, in the management of difficult diseases. Interest again: refractory arterial hypertension, a condition for which there are few or no alternative therapies.»

The results of the FRESH study, presented at the AHA conference, represent the first important step toward submission of registration dossiers to authorities in the United States and Europe.

The FRESH trial is the first pivotal Phase 3 trial to evaluate the efficacy and safety of filibastat in the treatment of difficult-to-treat and resistant arterial hypertension. 515 patients with difficult-to-treat or refractory hypertension were randomized to 69 hospitals in Europe, Canada, the United States and Latin America.

Enrollment for the REFRESH trial, the second pivotal Phase 3 long-term efficacy and safety study of the once-daily formulation of filibastat, is progressing successfully.

About quantum genomics

Quantum Genomics is a biopharmaceutical company focused on developing a new class of cardiovascular drugs based on mechanisms of inhibition of Brain Aminopeptidase A Inhibition or BAPAI. The only company in the world to pursue this innovative approach that directly targets the brain, he from the University of Paris Descartes and his INSERM/CNRS Institute led by Dr. Catherine Lawrence-Cortez of the French Secondary School based on more than 20 years of research. Quantum genomics can thus be applied to complex or even refractory arterial hypertension (about 30% of patients are uncontrolled or unsuccessful in treatment), and heart failure (1 in 2 patients diagnosed with 5 death within a year), we aim to develop an innovative treatment.

Based in Paris and New York, the company is listed on the Euronext Growth market in Paris (FR0011648971 – ALQGC) and registered on the American market OTCQX (symbol: QNNTF).

For more information, please visit www.quantum-genomics.com, our Twitter and Linkedin accounts.

contact address

quantum genomics

[email protected]

Communication building (Europe)

Financial communications and media

Quantum [email protected]

Life Science (USA)

Mike Tutley

media communication

+1 (646) 751-4362 – [email protected]

This post has a service called “🔒 Actusnews SECURITY MASTER”.

– Security Master Key:


– To find this key:


Regulatory information:

Inside information:

– Other press releases

Full press release and original in PDF format:


© Copyright Actusnews Wire

Sign up for www.actusnews.com to receive the company’s next press release by email, free of charge


Leave a Comment

Your email address will not be published.